Citeline Podcasts

Scrip’s Five Must-Know Things – 20 June 2022 by Citeline

世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。

For listeners in the pharma industry, we deliver a summarized insight from Scrip and Pink Sheet in Japanese, one story at a time.

今回取り上げた記事はこちら

The article for this episode is:

US FDA’s ‘Mature’ Approach To Quality: ‘Encourage More, Punish Less’

（邦題意訳「FDA、薬の品質対策に新戦略　“ムチよりアメ”のQMM制度とは？」）

https://pink.pharmaintelligence.informa.com/PS146314/US-FDAs-Mature-Approach-To-Quality-Encourage-More-Punish-Less

【コンサルティングサービスのご紹介】

ファーマインテリジェンスのコンサルティングチームは、製薬やバイオ技術、医療機器といった分野で活躍する企業のお客様と緊密に連携し、個別の課題をピンポイントで解決します。開発途中の薬剤に関するビジネス機会評価や売上予測、価格予測をはじめ、医療経済評価モデルや臨床試験計画、ベンチマークの策定、協業戦略の策定やポートフォリオの優先順位評価など、幅広いニーズに応え、エビデンスに基づいた意思決定を支援します。今解決したい課題をお持ちの方、ぜひご相談ください。

担当者：今堀 逸太郎（[email protected]）

Scrip’s Five Must-Know Things – 13 June 2022 by Citeline

Join Brian Yang in this wide-ranging interview with top executives from Jiangsu Hengrui’s US subsidiary Luzsana, on topics ranging from innovation to going global, US approvals of China-made drugs and China’s regulatory harmonization efforts.

In this episode, I speak to Annika Greve from Loop and Terracycle about the work that those companies do reducing waste across industries. Loop works with companies like Bausch+Lomb to create packaging that can be bought, used, and then dropped off in big box stores where consumers regularly shop. We spoke about how greenwashing from companies can harm consumer trust in the industry, and how the relatively recent habit of disposability will ultimately drive how companies switch to sustainable practices.

Scrip’s Five Must-Know Things – 6 June 2022 by Citeline

In this edition of Device Week, Medtech Insight’s Barnaby Pickering discusses recent developments in the highly competitive continuous glucose monitoring space and editor Marion Webb explains the application of robotics to common blood sampling.

The archive of Medtech Insight's Device Week and the rest of Informa Pharma Intelligence’s podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn, and Spotify Podcasts:

https://medtech.pharmaintelligence.informa.com/podcasts

Medtech Insight articles addressing topics discussed in this episode:

Dexcom Kiboshes Insulet Merger Rumors:

https://medtech.pharmaintelligence.informa.com/MT145464/Dexcom-Kiboshes-Insulet-Merger-Rumors

FDA Clears Abbott’s Libre 3:

https://medtech.pharmaintelligence.informa.com/MT145463/FDA-Clears-Abbotts-Libre-3

Medtronic Starts Planned Portfolio Simplification With DaVita Renal Care Spin Off:

https://medtech.pharmaintelligence.informa.com/MT145461/Medtronic-Starts-Planned-Portfolio-Simplification-With-DaVita-Renal-Care-Spin-Off

Dexcom Rumored To Be In Talks To Acquire Insulet:

https://medtech.pharmaintelligence.informa.com/MT145442/Dexcom-Rumored-To-Be-In-Talks-To-Acquire-Insulet

Vitestro Introduces First Autonomous Phlebotomist Robot In Europe

https://medtech.pharmaintelligence.informa.com/MT145467/Vitestro-Introduces-First-Autonomous-Phlebotomist-Robot-In-Europe

Microbot Medical Hopes To Bring First Disposable Endovascular Robot To US Market:

https://medtech.pharmaintelligence.informa.com/MT145377/Microbot-Medical-Hopes-To-Bring-First-Disposable-Endovascular-Robot-To-US-Market

Speaking Of Medtech, Ep. 9: The Case For Compliance

In this episode of Speaking Of Medtech: Over the past decade or so the US FDA and many device makers have been advocating for quality over compliance, but what if promoting compliance was seen as a good goal for the medtech industry?

Medtech Insight articles addressing topics discussed in this episode:

• Opinion: The Case For Quality – AND Compliance

https://medtech.pharmaintelligence.informa.com/MT145406/Opinion-The-Case-For-Quality--AND-Compliance

• Quality Control & Compliance

https://medtech.pharmaintelligence.informa.com/policy-regulation/quality-control

Title: Korean-language Scrip article summary

보스턴으로 몰리는 한국 제약바이오업계의 기회와 도전

(Korean Biopharmas Rush To Boston: What Are The Challenges And Opportunities?)

Description: 최근 국내 제약바이오사들의 미국 진출이 더욱 활발해지고 있는 이유와 이 기업들이 미국에 진출할 때 특히 어떤 어려움을 겪고 있는 지에 대한 Scrip Intelligence의 인터뷰 기사를 요약한 내용입니다.

https://scrip.pharmaintelligence.informa.com/SC146422/Korean-Biopharmas-Rush-To-Boston-What-Are-The-Challenges-And-Opportunities

Ellie Davenport, Summer Colling, and Kripa Krishnan discuss the psychiatric disorder market and outlook, with a focus on schizophrenia, bipolar, and major depressive disorder.

Schizophrenia disease analysis report and forecast

https://service.datamonitorhealthcare.com/hkc/disease/central-nervous-system/psychiatry/schizophrenia/disease-analysis/article216769.ece

Bipolar disease analysis report and forecast

https://service.datamonitorhealthcare.com/hkc/disease/central-nervous-system/psychiatry/bipolar-disorder/disease-analysis/article219685.ece

Major depressive disorder disease analysis report and forecast

https://service.datamonitorhealthcare.com/hkc/disease/central-nervous-system/psychiatry/depression/disease-analysis/article220083.ece

Other platforms:

Apple Podcasts -   podcasts.apple.com/us/podcast/phar…sts/id923189836

Google Podcasts - podcasts.google.com/feed/aHR0cHM6Ly…C9zb3VuZHMucnNz

TuneIn - tunein.com/podcasts/Business--…-Podcasts-p1140128/

Spotify Podcasts - open.spotify.com/show/3DTc3eIh4xI6pVOd6DdO67